This is a national multi-center, large sample size case registration clinical study. The registry population was patients with inflammatory skin diseases who were receiving treatment with vunakizumab. All outpatient and inpatient patients with inflammatory skin diseases who were receiving vunakizumab were eligible for enrollment. Patients' usual care was not affected by participation in the study. We only collected data in routine clinical practice.

The study had an enrollment period of 5 years or 10,000 patients were recruited early, whichever occurred first. All patients must provide written informed consent form before data collection, and each patient will be followed for 1 year to observe clinical progression.

Inclusion Criteria:

• aged ≥ years；
• had adiagnosis of inflammatory skin disease；
• Is receiving or plans to receive vunakizumab for treatment;
• Patients provided written informed consent form.

Exclusion Criteria:

• no.

Patients woh had adiagnosis of inflammatory skin disease are receiving or plans to receive vunakizumab for treatment.